Discovery Parks | Tenant News

June 24 Discovery Parks Vancouver Tech Park Developer Recognized for Green Building Leadership
May 20 Discovery Parks Discovery Parks receives energy conservation award
May 20 Discovery Parks Discovery Parks Trust Recognized for Green Building Leadership
April 16 Chemokine Therapeutics Chemokine Therapeutics Announces New President and Chief Executive Officer
April 7 Chemokine Therapeutics Chemokine Therapeutics Announces 2007 Financial Operating Results
March 17 Cardiome Cardiome announces positive interim phase 2b results for oral vernakalant and engages Merrill Lynch as strategic advisor
February 28 Chemokine Therapeutics Chemokine Therapeutics Announces the Publication of Study Results
February 21 Chemokine Therapeutics Chemokine Therapeutics announces three abstracts accepted for presentation at the AACR annual meeting on its lead drug candidate CTCE-9908
February 11 Amorfix Life Sciences Amorfix presents results from British blinded panel of spiked Human blood samples
February 8 Amorfix Life Sciences Amorfix announces third quarter fiscal 2008 results
February 1 Amorfix Life Sciences UK Government clarifies process to verify a blood test for vCJD and releases Amorfix blinded panel results
January 21 Cardiome Cardiome and Astellas announce regulatory update
January 4 Amorfix Life Sciences Amorfix Life Sciences appoints Aziz Mekouar as a member of board of directors

2007

December 18 Discovery Parks Discovery Parks Welcomes Private Equity Professional Venture Capitalist Darrell Elliott joins Board; Dr. Bernie Bressler Promoted to Chair
December 17 Chemokine Therapeutics Chemokine Therapeutics announces new directors
December 10 Chemokine Therapeutics Chemokine Therapeutics continues patient therapy using CTCE-9908 and extends closing of its phase I/II clinical trial
October 26 Chemokine Therapeutics Chemokine Therapeutics investigator present encouraging preliminary results from CTCE-9908 Phase I/II clinical trial
October 15 Neuromed Neuromed Concludes a Special Protocol Assessment (SPA) with FDA for a Pivotal Phase 3 Study on NMED-1077
October 10 Chemokine Therapeutics Two additional abstracts accepted for presentation at the upcomining Molecular Targets and Cancer Therapeutics International Conference
October 5 Neuromed Neuromed President & CEO Dr. Christopher Gallen Named Finalist for Scrip Award's "Executive of the Year"
October 2 Chemokine Therapeutics Chemokine Therapeutics completes patient recruitment of CTCE-9908 Phase I/II clinical trial
September 19 Chemokine Therapeutics Juravinski Cancer Centre investigator to present Phase I/II Data at the Molecular targets ....
August 21 Neuromed Neuromed Raises US$53.3 Million in Series E Financing to Accelerate Development of Pain Treatments
August 8 Neuromed Neuromed Announces that Merck & Co., Inc. Discontinues Development of Pain Drug Candidate, Joint Research Program Continues
August 2 Neuromed Neuromed Appoints Mario Orlando as Vice President of Marketing
July 9 Neuromed Neuromed Appoints Dr. William L. Hunter as Chairman of the Board of Directors
Jun 19 Neuromed Neuromed President & CEO Dr. Christopher Gallen named "100 Most Inspiring People in the Life Sciences Industry"
May 30 Chemokine Therapeutics Chemokine Therapeutics files for a public offering of units
April 24 Neuromed Neuromed licenses Phase 3 Chronic Pain Products from ALZA Corporation
March 22 Chemokine Therapeutics Chemokine Therapeutics announces addition to senior management team
March 12 Chemokine Therapeutics Chemokine Therapeutics announces preliminary results of CTCE-9908 Phase IB/II Clinical trial in late stage cancer patients